Although AstraZeneca missed the consensus estimates for both earnings per share and sales, the year-over-year growth in both metrics suggests a positive trajectory. The miss might cause some short-term negative sentiment, but the growth indicates underlying strength. Therefore, the impact on the stock price is likely to be neutral in the short term as investors weigh the miss against the growth.